Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19242489 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | June 2025 | December 2025 | Allow | 6 | 0 | 1 | Yes | No |
| 19213047 | CEVIMELINE LIQUID FORMULATIONS | May 2025 | December 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 19023371 | TETRAZINE COMPOUND CAPABLE OF HAVING RAPID CYCLOADDITION REACTION WITH NON-STRAINED OLEFINIC BORONIC ACID AND BIOMEDICAL APPLICATION THEREOF | January 2025 | November 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18852508 | SAFE AND STABLE NIMODIPINE FORMULATION FOR INJECTION AND METHOD FOR PREPARING SAME | September 2024 | March 2026 | Allow | 17 | 1 | 1 | Yes | No |
| 18826887 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | September 2024 | November 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18827622 | USE OF REBOXETINE TO TREAT NARCOLEPSY | September 2024 | November 2025 | Abandon | 14 | 2 | 0 | No | No |
| 18758225 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | June 2024 | July 2025 | Allow | 13 | 2 | 0 | No | No |
| 18705978 | SHP2 AND CDK4/6 DUAL-TARGET INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | April 2024 | January 2025 | Allow | 9 | 0 | 1 | Yes | No |
| 18632991 | Acyclic Thiol Prodrugs | April 2024 | May 2025 | Abandon | 13 | 0 | 1 | No | No |
| 18421660 | ANTHELMINTIC HETEROCYCLIC COMPOUNDS | January 2024 | January 2025 | Allow | 12 | 1 | 0 | No | No |
| 18578864 | MANDELATE FORM OF 1-(4-(((6-AMINO-5-(4-PHENOXYPHENYL)PYRIMIDIN-4-YL)AMINO)METHYL)PIPERIDIN-1-YL)PROP-2-EN-1-ONE | January 2024 | March 2026 | Allow | 26 | 0 | 0 | Yes | No |
| 18510546 | BIPHENYL COMPOUND AS IMMUNOMODULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | November 2023 | November 2025 | Allow | 24 | 2 | 1 | No | No |
| 18502396 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | November 2023 | May 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18502972 | GLP-1R MODULATING COMPOUNDS | November 2023 | June 2025 | Allow | 19 | 1 | 1 | No | No |
| 18376981 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | October 2023 | May 2025 | Allow | 19 | 1 | 0 | No | No |
| 18479185 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | October 2023 | October 2024 | Allow | 12 | 0 | 0 | No | No |
| 18551491 | TYROSINASE-INHIBITING MOLECULES AND DERMOPHARMACEUTICAL COMPOSITION THAT INCLUDES THEM | September 2023 | January 2026 | Allow | 28 | 0 | 0 | No | No |
| 18460428 | Pyrazolopyridine Derivatives and Uses thereof | September 2023 | May 2024 | Allow | 9 | 0 | 0 | Yes | No |
| 18446522 | HODGKIN LYMPHOMA THERAPY | August 2023 | June 2025 | Allow | 22 | 2 | 0 | No | No |
| 18359136 | PROCESS FOR THE MANUFACTURING OF (6AR,10AR)-7-PROPYL-6,6A,7,8,9,10,10A,11-OCTAHYDRO-[1,3]DIOXOLO[4',5':5,6]BENZO[1,2-G]QUINOLINE AND (4AR,10AR)-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDRO-BENZO[G]QUINOLINE-6,7-DIOL | July 2023 | February 2025 | Allow | 18 | 0 | 1 | No | No |
| 18223652 | PYRIMIDINE DERIVATIVE AND PREPARATION PROCESS AND USE THEREOF | July 2023 | December 2024 | Allow | 17 | 1 | 0 | No | No |
| 18348078 | CRYSTALLINE PSILACETIN DERIVATIVES | July 2023 | July 2024 | Allow | 13 | 0 | 0 | Yes | No |
| 18213407 | METHODS OF TREATING NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY USING MODIFIED FORMS OF TRIMETAZIDINE | June 2023 | October 2024 | Allow | 16 | 1 | 1 | No | No |
| 18317990 | CARBOXAMIDE DERIVATIVES | May 2023 | October 2025 | Allow | 29 | 2 | 1 | Yes | No |
| 18190244 | HIGH PURITY 2-NAPHTHYLACETONITRILE AND METHOD FOR PRODUCING SAME | March 2023 | September 2024 | Allow | 17 | 1 | 0 | No | No |
| 18041030 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | February 2023 | September 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18084237 | GROUP VI PRECURSOR COMPOUNDS | December 2022 | August 2024 | Allow | 19 | 3 | 0 | Yes | No |
| 18064204 | READY-TO-USE ASCORBIC ACID COMPOUND COMPOSITIONS | December 2022 | July 2024 | Allow | 19 | 4 | 0 | No | No |
| 18063766 | QUINOLINE DERIVATIVES | December 2022 | November 2024 | Allow | 23 | 2 | 0 | No | No |
| 18049966 | METHODS OF TREATING HEAD AND NECK CANCERS WITH HEMP EXTRACT | October 2022 | December 2025 | Allow | 37 | 5 | 0 | Yes | No |
| 17913126 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | September 2022 | July 2025 | Allow | 34 | 3 | 1 | No | No |
| 17896182 | COVALENT INHIBITORS OF CORONAVIRUS PAPAIN-LIKE PROTEASE | August 2022 | October 2024 | Allow | 26 | 0 | 1 | No | No |
| 17893081 | CONJUGATION-FUSED BIPOLAR REDOX-ACTIVE MOLECULE, PREPARATION METHOD, AND APPLICATION THEREOF | August 2022 | March 2026 | Allow | 43 | 1 | 1 | No | No |
| 17801450 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | August 2022 | April 2025 | Allow | 32 | 0 | 0 | No | No |
| 17796449 | GCN2 MODULATOR COMPOUNDS | July 2022 | January 2026 | Allow | 42 | 1 | 0 | No | No |
| 17860148 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | July 2022 | March 2025 | Allow | 32 | 3 | 1 | No | No |
| 17728575 | PROCESS FOR SYNTHESIZING APREMILAST | April 2022 | November 2024 | Allow | 31 | 2 | 1 | No | No |
| 17704440 | KHK INHIBITORS | March 2022 | August 2024 | Allow | 28 | 3 | 1 | Yes | No |
| 17687550 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | March 2022 | March 2025 | Allow | 37 | 0 | 1 | No | No |
| 17684164 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | March 2022 | October 2025 | Allow | 43 | 1 | 0 | No | No |
| 17634524 | A METHOD FOR PREPARING IVOSIDENIB AND AN INTERMEDIATE THEREOF | February 2022 | July 2025 | Allow | 41 | 0 | 0 | No | No |
| 17634367 | ENZYME INHIBITORS | February 2022 | December 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17630537 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | January 2022 | June 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17629024 | N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES | January 2022 | May 2025 | Allow | 40 | 1 | 0 | No | No |
| 17628496 | DOMINANT SALT FORMS OF PYRIMIDINE DERIVATIVES, AND CRYSTAL FORMS THEREOF | January 2022 | December 2024 | Allow | 35 | 0 | 0 | Yes | No |
| 17627391 | USE OF A BENZOATE CONTAINING COMPOSITION TO TREAT NEURODEGENERATIVE DISORDERS | January 2022 | September 2025 | Allow | 44 | 0 | 1 | Yes | No |
| 17627084 | NLRP3 MODULATORS | January 2022 | February 2025 | Allow | 37 | 1 | 0 | No | No |
| 17570693 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | January 2022 | April 2025 | Allow | 39 | 1 | 0 | No | No |
| 17621871 | A Substituted Tetrahydroisoquinoline Derivative as a D1 Positive Allosteric Modulator | December 2021 | February 2025 | Allow | 38 | 1 | 0 | No | No |
| 17621284 | SOLID STATE FORMS OF ROLUPERIDONE AND SALTS THEREOF | December 2021 | June 2025 | Allow | 42 | 0 | 0 | No | No |
| 17618971 | SMALL CATIONIC ORTHO-5,15-DI-HETEROARYL-PORPHYRIN DERIVATIVES AND THEIR APPLICATIONS IN PHOTOINACTIVATION OF MICROORGANISMS | December 2021 | June 2025 | Allow | 42 | 1 | 0 | No | No |
| 17548352 | TREATMENT OF SMA | December 2021 | November 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17614973 | CRYSTALLINE POLYMORPHS OF A 1-THIAZOL-2-YL-PYRAZOLE-5-CARBOXYLIC ACID DERIVATIVE | November 2021 | February 2025 | Allow | 39 | 1 | 0 | No | No |
| 17611684 | OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE | November 2021 | June 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17435901 | METHODS AND COMPOSITIONS FOR SUBSTITUTED AXIALLY-CHIRAL CANNABINOL ANALOGS | September 2021 | November 2025 | Allow | 51 | 3 | 1 | Yes | No |
| 17432776 | a-SYNUCLEIN AGGREGATE BINDING AGENT AND IMAGING METHOD | August 2021 | October 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17310673 | A PROCESS FOR PREPARING ANTHRANILIC DIAMIDES AND INTERMEDIATES THEREOF | August 2021 | May 2025 | Allow | 45 | 1 | 1 | No | No |
| 17431408 | N-Aryl Benzenesulfonamides as Protonophores for the Treatment of Cancers, Metabolic Diseases and Traumatic Brain Injury | August 2021 | December 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17304828 | COMPOSITIONS AND METHODS FOR BLOCKING SODIUM CHANNELS | June 2021 | April 2025 | Allow | 46 | 4 | 1 | No | No |
| 17351970 | USES OF P53 X-RAY CO-CRYSTAL STRUCTURES | June 2021 | October 2025 | Allow | 52 | 3 | 1 | Yes | No |
| 17286716 | BETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORS | April 2021 | December 2025 | Allow | 56 | 2 | 1 | No | No |
| 17281659 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY NEUROLOGICAL DISORDERS | March 2021 | August 2025 | Allow | 52 | 1 | 1 | Yes | No |
| 17275405 | COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR | March 2021 | December 2025 | Abandon | 57 | 2 | 1 | No | No |
| 17259975 | THIADIAZINE DERIVATIVES | January 2021 | December 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 17258894 | METHODS AND COMPOSITIONS FOR PROMOTING WOUND HEALING IN A SUBJECT SUFFERING FROM ECTODERMAL DYSPLASIAS | January 2021 | September 2025 | Allow | 57 | 3 | 1 | No | No |
| 17255719 | PYRIMIDINE DERIVATIVE AND PREPARATION PROCESS AND USE THEREOF | December 2020 | September 2024 | Allow | 45 | 3 | 1 | Yes | No |
| 17254982 | METHODS FOR TREATING AGITATION USING DEXMEDETOMIDINE HYDROCHLORIDE | December 2020 | September 2025 | Abandon | 57 | 1 | 1 | No | No |
| 17255349 | HYPERICIN-PVP COMPLEX WITH HIGH HYPERICIN CONTENT | December 2020 | July 2024 | Allow | 43 | 0 | 1 | No | No |
| 16972898 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF KIDNEY DAMAGE | December 2020 | October 2024 | Allow | 46 | 1 | 0 | No | No |
| 17055332 | STABLE AQUEOUS HYDROXYCARBAMIDE SOLUTION | November 2020 | August 2024 | Allow | 45 | 1 | 0 | No | No |
| 17047778 | METHODS OF TREATING CANCER | October 2020 | November 2024 | Allow | 49 | 3 | 0 | No | No |
| 17046533 | USE OF A NOVEL COMPOSITION FOR PREVENTING OR SLOWING DOWN THE APPEARANCE OF UNSIGHTLY SIGNS RELATING TO THE PRESENCE OF EXCESS SEBUM | October 2020 | November 2025 | Abandon | 60 | 4 | 0 | No | No |
| 16965252 | Recognition ability improving agent | July 2020 | January 2026 | Allow | 60 | 5 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner KUCHARCZK, JED A works in Art Unit 1623 and has examined 25 patent applications in our dataset. With an allowance rate of 72.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 47 months.
Examiner KUCHARCZK, JED A's allowance rate of 72.0% places them in the 35% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by KUCHARCZK, JED A receive 1.72 office actions before reaching final disposition. This places the examiner in the 36% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by KUCHARCZK, JED A is 47 months. This places the examiner in the 8% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +35.0% benefit to allowance rate for applications examined by KUCHARCZK, JED A. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 34.6% of applications are subsequently allowed. This success rate is in the 77% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 22.2% of allowed cases (in the 94% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.